UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000000523 |
|---|---|
| Receipt number | R000000633 |
| Scientific Title | Phase III trial of upfront debulking surgery vs. neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers (JCOG0602, OV-NACTC-P3) |
| Date of disclosure of the study information | 2006/11/17 |
| Last modified on | 2016/09/13 11:38:14 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase III trial of upfront debulking surgery vs. neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers (JCOG0602, OV-NACTC-P3)
Acronym
Phase III trial of upfront debulking surgery vs. neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers (JCOG0602, OV-NACTC-P3)
Scientific Title
Phase III trial of upfront debulking surgery vs. neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers (JCOG0602, OV-NACTC-P3)
Scientific Title:Acronym
Phase III trial of upfront debulking surgery vs. neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers (JCOG0602, OV-NACTC-P3)
Region
| Japan |
Condition
Condition
stage III/IV mullerian carcinomas such as ovarian, tubal and peritoneal carcinomas
Classification by specialty
| Obstetrics and Gynecology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To compare the usefulness of neoadjuvant chemotherapy with current standard treatment procedure, debulking surgery in advance of chemotherapy, in patients with stage III/IV ovarian, tubal and peritoneal cancers.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Developmental phase
Phase III
Assessment
Primary outcomes
overall survival
Key secondary outcomes
proportion of clinical complete remission, progression free survival, response rate, adverse event, surgical invasiveness
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
NO
Dynamic allocation
YES
Institution consideration
Institution is considered as adjustment factor in dynamic allocation.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine | Maneuver |
Interventions/Control_1
A: Primary debulking surgery followed by chemotherapy
Interventions/Control_2
B: Neoaduvant chemptherapy followed by interval debulking surgery
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | >= |
Gender
Female
Key inclusion criteria
1) stage III or IV mullerian carcinoma by clinical findings including imaging studies (CT or MRI) and cytology of ascites, pleural effusions, or fluids obtained by tumor centesis
2) clinically deemed to be a candidate for debulking surgery without evidence of brain, bone, bone marrow metastasis
3) CA125>200U/mL and CEA<20ng/mL
4) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3
5) presence of any measurable lesions is not required
6) previously untreated for these malignancies and no history of treatment with chemotherapy nor radiotherapy even for other diseases
7) adequate bone marrow, hepatic, renal, cardiac and respiratory functions
8) written informed consent
Key exclusion criteria
1) synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ
2) pregnant or nursing
3) severe mental disorders
4) systemic and continuous use of steroidal drugs
5) positive for serum hepatitis B surface antigen
6) active infections
7) uncontrolled hypertension
8) diabetes mellitus, uncontrolled or controlled with insulin
9) history of cardiac failure, unstable angina, myocardial infarction within 6 months prior to the registration
10) hypersensitivity to polyoxyethylated castor oill
11) intestinal occlusion necessary for surgical treatment
12) hypersensitivity to alcohol
Target sample size
300
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Hiroyuki Yoshikawa |
Organization
Ibaraki Prefectural Central Hospita
Division name
Department of Obstetrics and Gynecology
Zip code
Address
6528 Koibuchi, Kasama, Ibaraki 309-1793, JAPAN
TEL
0296-77-1121
h-yoshikawa@chubyoin.pref.ibaraki.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Takashi Onda |
Organization
JCOG0602 Coordinating Office
Division name
Department of Obstetrics and Gynecology School of Medicine, Kitasato University Hospital
Zip code
Address
1-15-1, Kitasato,Sagamihara-shi,Kanagawa 252-0375, JAPAN
TEL
042-778-8111
Homepage URL
http://www.jcog.jp/
JCOG_sir@ml.jcog.jp
Sponsor or person
Institute
Japan Clinical Oncology Group(JCOG)
Institute
Department
Personal name
Funding Source
Organization
Ministry of Health, Labour and Welfare
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
北海道大学病院（北海道）
札幌医科大学（北海道）
岩手医科大学（岩手県）
東北大学病院（宮城県）
筑波大学医学医療系（茨城県）
防衛医科大学校（埼玉県）
埼玉県立がんセンター（埼玉県）
埼玉医科大学総合医療センター（埼玉県）
東京慈恵会医科大学附属柏病院（千葉県）
国立がん研究センター中央病院（東京都）
がん・感染症センター都立駒込病院（東京都）
東京慈恵会医科大学附属病院（東京都）
がん研究会有明病院（東京都）
東京大学医学部（東京都）
順天堂大学医学部附属順天堂医院（東京都）
NTT東日本関東病院（東京都）
北里大学医学部（神奈川県）
新潟県立がんセンター新潟病院（新潟県）
信州大学医学部（長野県）
愛知県がんセンター中央病院（愛知県）
名古屋大学医学部（愛知県）
京都大学医学部附属病院（京都府）
大阪市立大学医学部附属病院（大阪府）
近畿大学医学部（大阪府）
大阪府立病院機構大阪府立成人病センター（大阪府）
大阪市立総合医療センター（大阪府）
近畿大学医学部堺病院（大阪府）
兵庫県立がんセンター（兵庫県）
鳥取大学医学部（鳥取県）
国立病院機構呉医療センター・中国がんセンター（広島県）
国立病院機構四国がんセンター（愛媛県）
国立病院機構九州がんセンター（福岡県）
久留米大学医学部（福岡県）
九州大学病院（福岡県）
佐賀大学医学部（佐賀県）
熊本大学医学部（熊本県）
鹿児島市立病院（鹿児島県）
琉球大学医学部（沖縄県）
Other administrative information
Date of disclosure of the study information
| 2006 | Year | 11 | Month | 17 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2006 | Year | 10 | Month | 18 | Day |
Date of IRB
Anticipated trial start date
| 2006 | Year | 11 | Month | 01 | Day |
Last follow-up date
| 2017 | Year | 11 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2006 | Year | 11 | Month | 17 | Day |
Last modified on
| 2016 | Year | 09 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000633
